Pharmacokinetics in children

The average Cmax and AUC values in paediatric patients, combined for age and gender, were comparable to the values observed in adults after an oral dose of 20 mg.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

For patients with moderate or severe renal function disorder, the recommended initial dose is 10 mg/day

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• CARDIOVASCULAR SYSTEM
• LIPID MODIFYING AGENTS

LIPID MODIFYING AGENTS, PLAIN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. Bristol Meyers Squibb BV, SPC Selektine (RVG 13755) 17-04-2015, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring

Overdose